Abstract
Background: Ischaemic stroke is often complicated with haemorrhage within the infarct zone or in a remote location especially when treated with intravenous thrombolysis and/or thrombectomy. While these early recanalisation treatments are highly effective, some of the benefit is lost because of haemorrhagic complications and consequential neurological deterioration of the patients. A number of mechanisms have been described that mediate the haemorrhagic changes and several agents have been tested in experimental models for inhibiting post-stroke haemorrhage.
Methods: Here, we review and discuss the small animal models of focal cerebral ischaemia and postischaemic stroke haemorrhagic transformation and how these models can best be utilised for developing further insights as well as potential treatment approaches for this serious clinical complication.
Results: The need to use appropriate animal models with relevant stroke risk factors to improve the clinical relevance and applicability of findings is becoming ever more apparent. Current focal ischaemia models can be adapted for the study of haemorrhagic transformation post-stroke.
Conclusion: A number of factors can be added to the animal model design to increase the incidence and/or severity of haemorrhagic transformation post-ischaemic stroke, which can improve clinical relevance, aid the study of the pathophysiology and the future development of novel interventions.
Keywords: Focal cerebral ischaemia, ischaemic stroke, haemorrhagic transformation, animal models, thrombolysis, thrombectomy.
Current Vascular Pharmacology
Title:Animal Models of Focal Cerebral Ischaemia and Haemorrhagic Transformation: Considerations in Experimental Stroke Study Design
Volume: 16 Issue: 6
Author(s): J.A. Shearer, A.S. Douglas, B.P. Kirby, T. Tatlisumak and K.M. Doyle*
Affiliation:
- Physiology Department, Galway Neuroscience Centre and CURAM, National University of Ireland, Galway,Ireland
Keywords: Focal cerebral ischaemia, ischaemic stroke, haemorrhagic transformation, animal models, thrombolysis, thrombectomy.
Abstract: Background: Ischaemic stroke is often complicated with haemorrhage within the infarct zone or in a remote location especially when treated with intravenous thrombolysis and/or thrombectomy. While these early recanalisation treatments are highly effective, some of the benefit is lost because of haemorrhagic complications and consequential neurological deterioration of the patients. A number of mechanisms have been described that mediate the haemorrhagic changes and several agents have been tested in experimental models for inhibiting post-stroke haemorrhage.
Methods: Here, we review and discuss the small animal models of focal cerebral ischaemia and postischaemic stroke haemorrhagic transformation and how these models can best be utilised for developing further insights as well as potential treatment approaches for this serious clinical complication.
Results: The need to use appropriate animal models with relevant stroke risk factors to improve the clinical relevance and applicability of findings is becoming ever more apparent. Current focal ischaemia models can be adapted for the study of haemorrhagic transformation post-stroke.
Conclusion: A number of factors can be added to the animal model design to increase the incidence and/or severity of haemorrhagic transformation post-ischaemic stroke, which can improve clinical relevance, aid the study of the pathophysiology and the future development of novel interventions.
Export Options
About this article
Cite this article as:
Shearer J.A., Douglas A.S., Kirby B.P., Tatlisumak T. and Doyle K.M.*, Animal Models of Focal Cerebral Ischaemia and Haemorrhagic Transformation: Considerations in Experimental Stroke Study Design, Current Vascular Pharmacology 2018; 16 (6) . https://dx.doi.org/10.2174/1570161115666170906115300
DOI https://dx.doi.org/10.2174/1570161115666170906115300 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Emerging Therapy Options in Heparin-Induced Thrombocytopenia
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Feasibility and Efficacy of Low-profile Visual Intraluminal Support Device: A Single Center Five-year Experience
Current Neurovascular Research Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Update on Sirolimus Drug-Eluting Stents
Current Pharmaceutical Design Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Systemic Inflammatory Response, Bacterial Translocation and Nitric Oxide Donors
Inflammation & Allergy - Drug Targets (Discontinued) Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Sustained Delivery of Interferons by Micro- and Nanosystems
Recent Patents on Materials Science Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Immunopathology of Brucella Infection
Recent Patents on Anti-Infective Drug Discovery Contrast-Induced Nephropathy after Endovascular Aneurysm Repair, Carotid and Peripheral Interventions
Current Vascular Pharmacology Vascular Modeling from Volumetric Diagnostic Data: A Review
Current Medical Imaging Editorial
Current Medical Imaging Bench to Bedside of CTLA-4: A Novel Immuno-Therapeutic Agent for Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery An Old Drug with a New Purpose: Cardiovascular Actions of Acetaminophen (Paracetamol)
Current Drug Targets - Cardiovascular & Hematological Disorders Antiplatelet Treatment in Stroke: New Insights
Current Pharmaceutical Design